Research News
A successful first-in-human clinical study of YCT-529, a hormone-free birth control pill for men developed by Dr. Gunda Georg of the College of Pharmacy and YourChoice Therapeutics, demonstrated its safety.
Findings open new opportunities to seek BioB inhibitors to treat infections with M. tuberculosis and other pathogens.
Two-year training opportunity, funded by the National Center for Advancing Translational Sciences (NCATS), integrates a mentored full-time research experience and an individualized curriculum.